title: Prognostic significance of prostate-specific antigen levels two months after hormonal manipulation of metastatic prostate cancer.
abstract: OBJECTIVE
  To assess the prognostic significance of prostate-specific antigen (PSA) levels before and during therapy in patients with metastatic adenocarcinoma of the prostate receiving hormonal manipulation.
  
  
  METHODS
  The PSA levels before and during treatment, together with various clinicopathological parameters, were measured retrospectively in 48 patients with newly diagnosed metastatic prostate cancer. The prognostic importance of these measurements was analyzed by both univariate and multivariate techniques.
  
  
  RESULTS
  PSA levels 2 months after treatment were the most useful predictors of progression-free (p = 0.004) or cause-specific survival (p = 0.006) in a multivariate Cox proportional-hazard model including histologic grade, age, performance status and pretreatment hemoglobin.
  
  
  CONCLUSIONS
  We have found that a low PSA level 2 months after treatment is prognostically superior to conventional clinicopathological parameters, such as histologic grade, in patients with metastatic prostate cancer undergoing treatment by hormonal manipulation.
authors.affiliation: Department of Urology, Tokyo Metropolitan Tama Geriatric Hospital, Japan. 1178uro@med.tmd.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Kawakami
authors.forename: K
authors.initials: K
authors.lastname: Takagi
authors.forename: J
authors.initials: J
authors.lastname: Yonese
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.forename: I
authors.initials: I
authors.lastname: Fukui
authors.forename: T
authors.initials: T
authors.lastname: Kawai
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011863:Radioimmunoassay
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol; D017430:Prostate-Specific Antigen